Gürçay, N.; Demirağ, F.; Kaplan Yılmaz, M.B.; Öz, İ.; İnal Cengiz, T.; Koçanoğlu, A.; Karakaya, S.; Demir, Ö.F.
KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer. J. Clin. Med. 2026, 15, 5236.
https://doi.org/10.3390/jcm15135236
AMA Style
Gürçay N, Demirağ F, Kaplan Yılmaz MB, Öz İ, İnal Cengiz T, Koçanoğlu A, Karakaya S, Demir ÖF.
KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 2026; 15(13):5236.
https://doi.org/10.3390/jcm15135236
Chicago/Turabian Style
Gürçay, Nesrin, Funda Demirağ, Müzeyyen Burcu Kaplan Yılmaz, İlknur Öz, Tuba İnal Cengiz, Abdulkadir Koçanoğlu, Serdar Karakaya, and Ömer Faruk Demir.
2026. "KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer" Journal of Clinical Medicine 15, no. 13: 5236.
https://doi.org/10.3390/jcm15135236
APA Style
Gürçay, N., Demirağ, F., Kaplan Yılmaz, M. B., Öz, İ., İnal Cengiz, T., Koçanoğlu, A., Karakaya, S., & Demir, Ö. F.
(2026). KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 15(13), 5236.
https://doi.org/10.3390/jcm15135236
